Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Technology appraisal guidance
Reference number: TA178
Published:
Evidence
Review and download supporting evidence. Includes the full guideline if available.